POLH and cancer: POLH-deficient cells are even more sensitive (10-fold) to gemcitabine/cisplatin combination treatment [37], which is a commonly used clinical regimen for treating a wide spectrum of cancers, including bladder, pancreatic, ovarian, cervical, and non-small-cell lung cancers.